{"id":11748,"date":"2025-12-30T03:14:10","date_gmt":"2025-12-30T02:14:10","guid":{"rendered":"https:\/\/fomatmedical.com\/?page_id=11748"},"modified":"2026-04-22T14:06:24","modified_gmt":"2026-04-22T21:06:24","slug":"phase-ii-iii-capabilities","status":"publish","type":"page","link":"https:\/\/fomatmedical.com\/es\/phase-ii-iii-capabilities\/","title":{"rendered":"Capacidades de fase II-III"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Embedded sites, aligned Phase II to III<\/span><\/h1><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Phase II to III studies are delivered through an embedded model that connects community based medical practices, EMR based pre screening and centralized operations under one coordinated structure.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"|\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Embedded model in practice <\/span><\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n \n\n<\/svg><\/span> <\/div>\n\n
\n
Research staff based inside partner medical practices <\/h5>\n\n \n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n \n\n<\/svg><\/span> <\/div>\n\n
\n
Central teams for contracts, budgets, regulatory and finance<\/h5>\n\n \n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n \n\n<\/svg><\/span> <\/div>\n\n
\n
Large EMR based database of active patients across these practices<\/h5>\n\n \n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n \n\n<\/svg><\/span> <\/div>\n\n
\n
Digital systems for eSource, dashboards and real time study oversight <\/h5>\n\n \n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n EXPLORE MORE <\/span><\/span>\n <\/a>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Phase II to III at a glance<\/span><\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n <\/g><\/g> <\/path> <\/g> <\/g><\/svg><\/span> <\/div>\n\n
\n
Aligned operations <\/h5>\n\n

Outpatient research sites and dedicated recruitment locations in California work under one coordinated clinical, regulatory, quality, and operations structure, supporting consistent execution and representative participation with 76.88% diverse enrollment across all studies.<\/p><\/div>\n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n <\/g><\/g> <\/path> <\/g><\/svg><\/span> <\/div>\n\n
\n
Faster activation <\/h5>\n\n

Because research is already embedded in existing practices and start up follows a single playbook, studies move from award to first patient on shorter timelines, including our 6 day record today companywide.<\/p><\/div>\n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n <\/g><\/g><\/path><\/g><\/svg><\/span> <\/div>\n\n
\n
Engaged participants <\/h5>\n\n

Participants are identified through EMR, physician referrals, and local outreach, and they often hear about studies from physicians they already know, with follow up in their preferred language. 91.30% enroll internally overall.<\/p><\/div>\n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n\n
\n <\/g><\/g> <\/rect> <\/path> <\/g><\/svg><\/span> <\/div>\n\n
\n
Quality built in <\/h5>\n\n

Sites are ready for eSource, eConsent, eRegulatory, and remote monitoring, while teams review activity throughout study. We complete 100% QC and 5 patients\u2019 first 5 visits within 48 hours, supporting 93.48% retention.<\/p><\/div>\n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Early phase and Phase I unit<\/span><\/span>\u00a0<\/span><\/span><\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Alongside outpatient Phase II to III studies, FOMAT also operates a dedicated early phase unit for first-in-human studies, intensive safety monitoring, and complex PK and PD work.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\n
\n
\n Check Phase I <\/span><\/span>\n <\/a>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"FOMAT\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Therapeutic areas we support<\/span><\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

FOMAT runs outpatient studies across multiple specialties, including<\/p>

  • Allergy and immunology<\/span>\u00a0<\/span><\/li>
  • Cardiology<\/span><\/span>\u00a0<\/span><\/li>
  • Dermatology<\/span><\/span>\u00a0<\/span><\/li>
  • Endocrinology and metabolic disorders<\/span><\/span><\/li>
  • Family medicine and internal medicine<\/span><\/span><\/li>
  • Gastroenterology and hepatology<\/span><\/span><\/li>
  • Infectious diseases and vaccines<\/span><\/span><\/li>
  • Nephrology<\/span><\/span><\/li>
  • Neurology<\/span><\/span><\/li>
  • Oncology<\/span><\/span><\/li>
  • Ophthalmology and retina<\/span><\/span><\/li>
  • Pediatrics and adolescents<\/span><\/span><\/li>
  • Rheumatology<\/span><\/span><\/li>
  • Urology<\/span><\/span><\/li>
  • Wound care and related specialties<\/span><\/span>\u00a0<\/span><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Los estudios de fase II a III se llevan a cabo mediante un modelo integrado que conecta las pr\u00e1cticas m\u00e9dicas comunitarias, la preselecci\u00f3n basada en EMR y las operaciones centralizadas bajo una estructura coordinada. Adem\u00e1s de los estudios ambulatorios de fase II a III, FOMAT tambi\u00e9n opera un programa espec\u00edfico de detecci\u00f3n temprana...<\/p>","protected":false},"author":2,"featured_media":86497,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11748","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/pages\/11748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=11748"}],"version-history":[{"count":146,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/pages\/11748\/revisions"}],"predecessor-version":[{"id":87284,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/pages\/11748\/revisions\/87284"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/86497"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=11748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}